Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared on LinkedIn, adding:
”Today is Rare Disease Day.
I work actively in the field of rare diseases, where progress often depends on rigorous research, multidisciplinary collaboration, and responsible clinical decision-making.
This image captures a milestone in our clinical practice: in September 2024, we administered the first gene therapy for Hemophilia A in our center.
Innovation in rare diseases is never abstract.
It is built carefully, through evidence, integrity, and high standards especially when patient numbers are small and every decision carries weight.
Raising awareness matters.
Building reliable evidence matters even more.
In rare diseases, small numbers require higher standards not lower ones.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome
-
Sep 20, 2026, 09:05World Stroke Academy: Can Adjunct IAT Improve Tissue Reperfusion?
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?